Full Text Journal Articles by
Author Burton M Needles

Advertisement

Find full text journal articles








Journey from oncologist to cancer survivor and patient advocate in the era of precision medicine.

Burton M Needles,

In 2013, the American Association for Cancer Research (AACR) introduced the "Precision Medicine Series" of symposia. The goal of these conferences is to "highlight the incredible technology and advances in cancer research that together are enabling treatments that are precisely targeted to the unique molecular and genetic characteristics of an ... Read more >>

Cold Spring Harb Mol Case Stud (Cold Spring Harbor molecular case studies)
[2018, 4(2):]

Cited: 0 times

View full text PDF listing >>



Achieving Coordinated Care for Patients With Complex Cases of Cancer: A Multiteam System Approach.

Simon J Craddock Lee, Mark A Clark, John V Cox, Burton M Needles, Carole Seigel, Bijal A Balasubramanian,

Patients with cancer with multiple chronic conditions pose a unique challenge to how primary care and specialty care teams provide well-coordinated, patient-centered care. Effectiveness of these care teams in providing optimal health care depends on the extent to which they coordinate their goals and knowledge as components of a multiteam ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2016, 12(11):1029-1038]

Cited: 6 times

View full text PDF listing >>



Advertisement

Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial.

Vera Hirsh, Pierre Desjardins, Burton M Needles, James R Rigas, Mohammad Jahanzeb, Laurent Nguyen, Denise Zembryki, Lance H Leopold,

OBJECTIVES: Many patients with metastatic nonsmall cell lung carcinoma (NSCLC) cannot tolerate intravenous chemotherapy. Orally active agents would be more convenient and thus could improve their quality of life. METHODS: A total of 189 patients were randomized 2:1, 181 patients received treatment, 120 PO and 61 IV vinorelbine, 158 patients ... Read more >>

Am. J. Clin. Oncol. (American journal of clinical oncology)
[2007, 30(3):245-251]

Cited: 7 times

View full text PDF listing >>



Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.

Stephanie R Land, Jacek A Kopec, Reena S Cecchini, Patricia A Ganz, H Samuel Wieand, Linda H Colangelo, Kate Murphy, J Philip Kuebler, Thomas E Seay, Burton M Needles, James D Bearden, Lauren K Colman, Keith S Lanier, Eduardo R Pajon, David Cella, Roy E Smith, Michael J O'Connell, Joseph P Costantino, Norman Wolmark,

PURPOSE: The randomized, multicenter, phase III protocol C-07 compared the efficacy of adjuvant bolus fluorouracil and leucovorin (FULV) versus FULV with oxaliplatin (FLOX) in stage II or III colon cancer. Definitive analysis revealed an increase in 4-year disease-free survival from 67.0% to 73.2% in favor of FLOX. This study compares ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2007, 25(16):2205-2211]

Cited: 95 times

View full text PDF listing >>





Advertisement

Disclaimer
0.9694 s